Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease

Trial Profile

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs 18FMNI 958 (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Most Recent Events

    • 15 Mar 2017 Planned number of patients changed from 6 to 9.
    • 07 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top